Predictors of Chemosensitivity in Triple Negative Breast Cancer: An Integrated Genomic Analysis
Jiang T, Shi W, Wali VB, Pongor L, Li C, Lau R, Győrffy B, Lifton RP, Symmans WF, Pusztai L, Hatzis C. Predictors of Chemosensitivity in Triple Negative Breast Cancer: An Integrated Genomic Analysis. PLOS Medicine 2016, 13: e1002193. PMID: 27959926, PMCID: PMC5154510, DOI: 10.1371/journal.pmed.1002193.Peer-Reviewed Original ResearchConceptsTriple-negative breast cancerPathologic complete responseMD Anderson Cancer CenterNegative breast cancerBreast cancerMutation burdenExtensive residual diseaseBetter survival outcomesBRCA deficiencyImmune cell activityAnderson Cancer CenterPredictor of chemosensitivityHigh mutation burdenWhole-exome sequencingACT chemotherapyMDACC cohortTNBC cohortNeoadjuvant chemotherapyCare chemotherapyTaxane chemotherapyCancer Genome AtlasComplete responseSuch patientsImproved survivalAggressive diseaseRelationship between Complete Pathologic Response to Neoadjuvant Chemotherapy and Survival in Triple-Negative Breast Cancer
Hatzis C, Symmans WF, Zhang Y, Gould RE, Moulder SL, Hunt KK, Abu-Khalaf M, Hofstatter EW, Lannin D, Chagpar AB, Pusztai L. Relationship between Complete Pathologic Response to Neoadjuvant Chemotherapy and Survival in Triple-Negative Breast Cancer. Clinical Cancer Research 2016, 22: 26-33. PMID: 26286912, DOI: 10.1158/1078-0432.ccr-14-3304.Peer-Reviewed Original ResearchConceptsPathologic complete responseRecurrence-free survivalTriple-negative breast cancerSurvival benefitNeoadjuvant trialsNeoadjuvant chemotherapyTrial populationBaseline prognosisBreast cancerOverall survival benefitComplete pathologic responseSignificant survival benefitPostneoadjuvant therapyPCR rateComplete responseImproved survivalPathologic responseSurvival improvementTreatment armsPatient survivalResidual diseaseControl armPrognostic variablesPatientsTrials